My Watchlist

Top Indices

NASDAQ Composite

Standard & Poors 500

My Portfolio

Articles published by Electra Therapeutics, Inc.

Electra Therapeutics Reports Third Quarter 2026 Financial Results and Recent Portfolio Highlights

November 12, 2026

From Electra Therapeutics, Inc.

Via GlobeNewswire

Tickers ETRA

Electra Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference in London

November 04, 2026

From Electra Therapeutics, Inc.

Via GlobeNewswire

Tickers ETRA

Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering

September 17, 2026

From Electra Therapeutics, Inc.

Via GlobeNewswire

Electra Therapeutics Announces Initiation of a Phase 1 Trial of ELA822, a Novel SIRPγ-Specific Antibody Designed to Treat T Cell-Mediated Immune and Inflammatory Diseases

September 10, 2026

From Electra Therapeutics, Inc.

Via GlobeNewswire

Electra Therapeutics Appoints Chris Clark, CFA, to Chief Financial Officer

September 09, 2026

From Electra Therapeutics, Inc.

Via GlobeNewswire

Electra Therapeutics Presents Positive Clinical Results From Completed Phase 1b Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) in an Oral Session at ASH 2024

December 09, 2024

From Electra Therapeutics, Inc.

Via Business Wire

Electra Therapeutics to Present Clinical Results for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) in an Oral Session at ASH 2024

November 05, 2024

From Electra Therapeutics, Inc.

Via Business Wire

Electra Therapeutics Receives FDA Fast Track Designation for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

November 04, 2024

From Electra Therapeutics, Inc.

Via Business Wire

Electra Therapeutics Receives FDA Orphan Drug Designation for ELA026 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

October 30, 2024

From Electra Therapeutics, Inc.

Via Business Wire

Electra Therapeutics Presents Late-Breaking Clinical Data at EHA2024 from Ongoing Phase 1b Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

June 16, 2024

From Electra Therapeutics, Inc.

Via Business Wire

Electra Therapeutics to Present ELA026 Clinical Data in Late-Breaking Oral Session at the 2024 European Hematology Association (EHA) Congress

June 03, 2024

From Electra Therapeutics, Inc.

Via Business Wire

Electra Therapeutics presents first clinical data from ongoing Phase 1b study of ELA026 for treatment of secondary hemophagocytic lymphohistiocytosis (sHLH)

December 11, 2023

From Electra Therapeutics, Inc.

Via Business Wire

Electra Therapeutics Appoints Kathy Dong, PharmD, MBA, as President and Chief Executive Officer

December 11, 2023

From Electra Therapeutics, Inc.

Via Business Wire

Electra Therapeutics to Present Clinical Data for ELA026 at the American Society of Hematology (ASH) 2023 Annual Meeting

November 02, 2023

From Electra Therapeutics, Inc.

Via Business Wire

Electra Therapeutics highlights ELA026 Phase 1b study in sHLH and presents preclinical data at ASH Annual Meeting

December 12, 2022

From Electra Therapeutics, Inc.

Via Business Wire

Electra Therapeutics to Highlight ELA026 in Three Presentations at the American Society of Hematology (ASH) 2022 Annual Meeting

November 03, 2022

From Electra Therapeutics, Inc.

Via Business Wire

Electra Therapeutics Announces $84 Million Series B Financing and Unveils Its Novel SIRP‑Targeted Therapies for Immunological Diseases and Cancer

February 16, 2022

From Electra Therapeutics, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.